BSEBeryl Drugs LtdMediumPositive
Announced Fri, 13 Mar · 15:27 IST

DISCLOSURE RECEIVED FROM MR. SUDHIR SETHI UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

Promoter Stake BuyCreeping Acquisition Near ThresholdOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.4%1-day move
₹20.99
prior close
₹20.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-8.3-4.7+0.0+2.0+0.0+19.1+13.6-2.3+12.0
Up moveDown movePending
AI summary

Mr. Sudhir Sethi, the main promoter of Beryl Drugs Ltd, has acquired 15,000 equity shares (0.29% of total share capital) through open market transactions on 12-03-2026. Following this acquisition, his holding in the company has increased from 4,55,143 shares (8.98%) to 4,70,143 shares (9.27%). The total share capital of the company remains unchanged at 50,71,700 shares. This is a small, incremental purchase by the promoter and falls under the disclosure requirement of Regulation 29(2) of SEBI Takeover Regulations.

Likely market impact

This is a minor, confidence-inspiring signal as the promoter is buying shares from the open market, though the small size (0.29%) suggests routine portfolio adjustment rather than a major strategic move. Shareholders may view it as a mild positive given the promoter is approaching the 10% substantial shareholder disclosure threshold.